Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
A Japanese health ministry panel on June 6 gave the thumbs-up for the approval of three new medicines, all designated as orphan drugs, including MSD’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan. Belzutifan, known as Welireg overseas, gained the backing…
To read the full story
Related Article
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- MSD’s Welireg, BMS’ Inrebic, J&J’s Talvey Up for Japan Panel Review on June 6
May 26, 2025
- MM Drug Talquetamab Filed in Japan: J&J
November 21, 2024
- MSD Files Belzutifan for von Hippel-Lindau Disease in Japan
September 18, 2024
- Rinvoq Filed for Giant Cell Arteritis in Japan: AbbVie
August 19, 2024
- Opdivo-Yervoy Combo Filed for HCC in Japan
August 13, 2024
- MSD Seeks Japan Nod for RCC Med Belzutifan
July 23, 2024
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





